Teijin Pharma Signs Gout Drug Marketing Rights Deal With Astellas Taiwan
This article was originally published in PharmAsia News
Executive Summary
Teijin Pharma of Japan May 12 signed a marketing agreement with Astellas Taiwan, a subsidiary of Astellas Pharmaceutical, which grants excusive marketing rights for gout durg Uloric (febuxostat) to Astellas in Taiwan. Positioned as one of Teijin's global products, febuxostat obtained approvals in Europe in April 2008. After obtaining U.S.FDA approval in February, it was marketed jointly with Takeda Pharmaceutical starting in March. In Asia, the drug is under review by Korea FDA. Taiwan has a high gout prevalence compared to other Asian countries. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.